Tarsus (TARS) HR chief settles RSUs, holds 47,302 common shares

Rhea-AI Filing Summary

Tarsus Pharmaceuticals, Inc. Chief Human Resources Officer Dianne C. Whitfield reported the settlement of vested Restricted Stock Units into common shares. On March 15, 2026, she exercised RSUs covering 23,909 underlying shares, resulting in direct ownership of 47,302 shares of common stock.

The RSUs were granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan on March 9, 2022, March 8, 2023, March 7, 2024, and March 5, 2025. Each grant vests in four equal annual installments on March 15 of consecutive years, subject to continuous service.

Insights

Equity compensation analyst

Routine RSU vesting and share issuance with no open-market selling.

The filing shows Dianne C. Whitfield, Chief Human Resources Officer of Tarsus Pharmaceuticals, Inc., settling vested Restricted Stock Units into 23,909 common shares on March 15, 2026. This is coded as an exercise or conversion of derivative securities, not a market purchase.

Following these settlements, she directly holds 47,302 common shares. Footnotes detail RSU grants from 2022 through 2025 that vest in four annual tranches each March 15, subject to continuous service. With no sales, this appears to be routine equity compensation rather than an active trading signal.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Whitfield Dianne C.

(Last) (First) (Middle)

C/O TARSUS PHARMACEUTICALS, INC.

15440 LAGUNA CANYON ROAD, SUITE 160

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tarsus Pharmaceuticals, Inc. [ TARS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Human Resources Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/15/2026		M		23,909	A	(1)	47,302	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	03/15/2026		M			4,463	(3)	(3)	Common Stock	4,463	$0	0	D
Restricted Stock Units	(2)	03/15/2026		M			7,248	(4)	(4)	Common Stock	7,248	$0	7,249	D
Restricted Stock Units	(2)	03/15/2026		M			7,176	(5)	(5)	Common Stock	7,176	$0	14,351	D
Restricted Stock Units	(2)	03/15/2026		M			5,022	(6)	(6)	Common Stock	5,022	$0	15,067	D

Explanation of Responses:

1. The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").

2. Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock.

3. RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs vested on March 15th of each of 2023, 2024, 2025 and 2026.

4. RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.

5. RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.

6. RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service.

Remarks:

	/s/ Jeffrey Farrow, Attorney-in-Fact	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Tarsus (TARS) disclose for Dianne C. Whitfield?

Tarsus reported that Chief Human Resources Officer Dianne C. Whitfield settled vested Restricted Stock Units into 23,909 shares of common stock on March 15, 2026. These were routine equity compensation conversions, not open-market stock purchases or sales.

How many Tarsus (TARS) shares does Dianne C. Whitfield hold after this Form 4?

After the RSU settlements reported, Dianne C. Whitfield directly owns 47,302 shares of Tarsus common stock. This total reflects the issuance of 23,909 shares upon conversion of vested Restricted Stock Units on March 15, 2026.

Were any Tarsus (TARS) shares sold in Dianne C. Whitfield’s latest Form 4?

No shares were reported sold. All transactions are coded as M, meaning exercise or conversion of derivative securities. The filing shows Restricted Stock Units converting into 23,909 common shares, increasing her direct holdings to 47,302 shares.

What are the vesting terms of Dianne C. Whitfield’s Tarsus (TARS) RSU awards?

Her RSUs were granted in 2022, 2023, 2024, and 2025 under the 2020 Stock Plan. Each grant vests in four equal installments on March 15 of consecutive years, subject to her continuous service with the company.

How do the Restricted Stock Units convert into Tarsus (TARS) common stock?

Each Restricted Stock Unit represents the right to receive one share of Tarsus common stock. When RSUs vest, they are settled in shares; this filing shows 23,909 underlying RSUs converting into the same number of common shares on March 15, 2026.

Which equity plan governs Dianne C. Whitfield’s Tarsus (TARS) RSU grants?

All reported RSU grants were issued under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. Grants dated March 9, 2022, March 8, 2023, March 7, 2024, and March 5, 2025 vest in four equal annual tranches each March 15, subject to continuous service.